Identifying the proteins constitutes in the necrosome complex in programmed cell death throughout necroptosis.

Abstract

Over recent years, immunotherapy has become an advanced and promising treatment against numerous types of cancers. However, as with any other innovative treatment, it shows noticeable challenges and complications. A combinatory therapy with the agents that induce necroptosis, a form of programmed cell death, can improve the effectiveness and broaden the spectrum of application of immunotherapies. This study aims to give an overview of the necrosome complex, which occurs during the process of necroptosis. A better understanding of the necrosome complex assemble, and its constituents may possibly reveal new therapeutical targets and benefit the efficiency of immunotherapy. To investigate the components of the necrosome complex, we used several cancer cell lines that potentially can undergo necroptosis. These cell lines were exposed to necroptotic treatment to form the necrosome complex. Further, the complex was isolated through co-immunoprecipitation, targeting a RIPK3 protein with an essential role in necroptosis. Lastly, we analysed isolated complex in a mass spectrometry-based set-up to identify present proteins